STK11

serine/threonine kinase 11

Basic information

Region (hg38): 19:1177558-1228431

Links

ENSG00000118046NCBI:6794OMIM:602216HGNC:11389Uniprot:Q15831AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Peutz-Jeghers syndrome (Strong), mode of inheritance: AD
  • Peutz-Jeghers syndrome (Strong), mode of inheritance: AD
  • Peutz-Jeghers syndrome (Supportive), mode of inheritance: AD
  • familial pancreatic carcinoma (Definitive), mode of inheritance: AD
  • Peutz-Jeghers syndrome (Definitive), mode of inheritance: AD
  • familial ovarian cancer (No Known Disease Relationship), mode of inheritance: AD
  • Peutz-Jeghers syndrome (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Peutz-Jeghers syndromeADGastrointestinal; OncologicRoutine surgical/endoscopic procedures can decrease the need of emergent procedures for sudden and severe sequelae (eg, intussusception); Surveillance for and early treatment of a variety of common malignancies (individuals may be at increased risk of a number of types of epithelial malignancies, including breast, cervical adenoma malignum, colorectal, gastric, ovarian, pancreatic cancers, sex cord tumors with annular tubules, and testicular Sertoli cell tumors) can be beneficialDermatologic; Gastrointestinal; Oncologic15399020; 14214503; 14279723; 5466889; 990720; 7436458; 3943856; 3697923; 3587280; 3181678; 2599445; 1986290; 7776109; 7802138; 9850045; 9428765; 9425897; 10408777; 10689645; 10874301; 11389158; 12044140; 15121768; 15200509; 15863673; 15617552; 20581245; 20301443

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the STK11 gene.

  • Peutz-Jeghers syndrome (154 variants)
  • Hereditary cancer-predisposing syndrome (92 variants)
  • not provided (26 variants)
  • Melanoma, cutaneous malignant, susceptibility to, 1 (4 variants)
  • Neoplasm (2 variants)
  • Carcinoma of pancreas (2 variants)
  • Melanoma (2 variants)
  • not specified (1 variants)
  • Gastric cancer (1 variants)
  • Malignant tumor of testis (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the STK11 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
5
clinvar
457
clinvar
2
clinvar
464
missense
10
clinvar
24
clinvar
851
clinvar
7
clinvar
892
nonsense
47
clinvar
4
clinvar
3
clinvar
54
start loss
1
clinvar
2
clinvar
3
frameshift
126
clinvar
14
clinvar
10
clinvar
150
inframe indel
4
clinvar
2
clinvar
24
clinvar
30
splice donor/acceptor (+/-2bp)
25
clinvar
23
clinvar
7
clinvar
55
splice region
2
1
47
56
5
111
non coding
1
clinvar
1
clinvar
75
clinvar
310
clinvar
50
clinvar
437
Total 214 68 977 774 52

Highest pathogenic variant AF is 0.00000657

Variants in STK11

This is a list of pathogenic ClinVar variants found in the STK11 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
19-1201926-G-A Likely benign (Jul 01, 2024)1701346
19-1205344-G-C Likely benign (Jun 01, 2024)1879405
19-1205491-A-G Likely benign (Jun 17, 2019)1204333
19-1205638-G-T Benign (Jan 10, 2019)1276994
19-1205798-G-GGCGTGTCGGGCGCGGAAGGGGGAGGCGGCCCGGGGCGCCCGCGAGTGAGGCGCGGGGCGGCGAAGGGAGCGCGGGTGGCGGCACTTGCTGCCGCGGCCTTGGATGGGCTGGGCCCCCCTCGCCGCTCCGCCTCCTCCACACGCGCGGCGGCCGCGGCGAGGGGGACGCGCCGCCCGGGGCCCGGCACCTTCGGGAACCCCCCGGCCCGGAGCCTGCGGCCTGCGCCGCCTCGGCCGCCGGGAGCCCCGTGGAGCCCCCGCCGCCGCGCCGCCCCGCGGACCGGACGCTGAGGGCACTCGGGGCGGGGCGCGCGCTCGGGCAGACGTTTGCGGGGAGGGGGGCGCCTGCCGGGCCCCGGCGACCACCTTGGGGGTCGCGGGCCGGCTCGGGGGGCGCCCAGTGCGGGCCCTCGCGGGCGCCGGGCAGCGACCAGCCCTGAGCGGAGCTGTTGGCCGCGGCGGGAGGCCTCCCGGACGCCCCCAGCCCCCCGAACGCTCGCCCGGGCCGGCGGGAGTCGGCGCCCCCCGGGAGGTCCGCTCGGTCGTCCGCGGCGGAGCGTTTGCTCCTGGGACAGGCGGTGGGACCGGGGCGTCGCCGGAGACGCCCCCAGCGAAGTTGGGCTCTCCAGGTGTGGGGGTCCCGGGGGGTAGCGACGTCGCGGACCCGGCCTGTGGGATGGGCGGCCCGGAGAAGACTGCGCTCGGCCGTGTTCATACTTGTCCGTGGGCCTGAGGTCCCCGGAGGATGACCTAGCACTGAAAAGCCCCGGCCGGCCTCCCCAGGGTCCCCGAGGACGAAGTTGACCCTGACCGGGCCGTCTCCCAGTTCTGAGGCCCGGGTCCCACTGGAACTCGCGTCTGAGCCGCCGTCCCGGACCCCCGGTGCCCGCCGGTCCGCAGACCCTGCACCGGGCTTGGACTCGCAGCCGGGACTGACGTGTAGAACAATCGTTTCTGTTGGAAGAAGGGTTTTTCCCTTCCTTTTGGGGTTTTTGTTGCCTTTTTTTTTTCTTTTTTCTTTGTAAAATTTTGGAGAAGGGAAGTCGGAACACAAGGAAGGACCGCTCACCCGCGGACTCAGGGCTGGCGGCGGGACTCCAGGACCCTGGGTCCAGCATGGAGGTGGTGGACCCGCAGCAGCTGGGCATGTTCACGGAGGGCGAGCTGATGTCGGTGGGTATGGACACGTTCATCCACCGCATCGACTCCACCGAGGTCATCTACCAGCCGCGCCGCAAGCGGGCCAAGCTCATCGGCAAGTACCTGATGGGGGACCTGCTGGGGGAAGGCTCTTACGGCAAGGTGAAGGAGGTGCTGGACTCGGAGACGCTGTGCAGGAGGGCCGTCAAGATCCTCAAGAAGAAGAAGTTGCGAAGGATCCCCAACGGGGAGGCCAACGTGAAGAA Uncertain significance (Dec 24, 2019)993156
19-1205798-GGCGTGTCGGGCGCGGAAGGGGGAGGCGGCCCGGGGCGCCCGCGAGTGAGGCGCGGGGCGGCGAAGGGAGCGCGGGTGGCGGCACTTGCTGCCGCGGCCTTGGATGGGCTGGGCCCCCCTCGCCGCTCCGCCTCCTCCACACGCGCGGCGGCCGCGGCGAGGGGGACGCGCCGCCCGGGGCCCGGCACCTTCGGGAACCCCCCGGCCCGGAGCCTGCGGCCTGCGCCGCCTCGGCCGCCGGGAGCCCCGTGGAGCCCCCGCCGCCGCGCCGCCCCGCGGACCGGACGCTGAGGGCACTCGGGGCGGGGCGCGCGCTCGGGCAGACGTTTGCGGGGAGGGGGGCGCCTGCCGGGCCCCGGCGACCACCTTGGGGGTCGCGGGCCGGCTCGGGGGGCGCCCAGTGCGGGCCCTCGCGGGCGCCGGGCAGCGACCAGCCCTGAGCGGAGCTGTTGGCCGCGGCGGGAGGCCTCCCGGACGCCCCCAGCCCCCCGAACGCTCGCCCGGGCCGGCGGGAGTCGGCGCCCCCCGGGAGGTCCGCTCGGTCGTCCGCGGCGGAGCGTTTGCTCCTGGGACAGGCGGTGGGACCGGGGCGTCGCCGGAGACGCCCCCAGCGAAGTTGGGCTCTCCAGGTGTGGGGGTCCCGGGGGGTAGCGACGTCGCGGACCCGGCCTGTGGGATGGGCGGCCCGGAGAAGACTGCGCTCGGCCGTGTTCATACTTGTCCGTGGGCCTGAGGTCCCCGGAGGATGACCTAGCACTGAAAAGCCCCGGCCGGCCTCCCCAGGGTCCCCGAGGACGAAGTTGACCCTGACCGGGCCGTCTCCCAGTTCTGAGGCCCGGGTCCCACTGGAACTCGCGTCTGAGCCGCCGTCCCGGACCCCCGGTGCCCGCCGGTCCGCAGACCCTGCACCGGGCTTGGACTCGCAGCCGGGACTGACGTGTAGAACAATCGTTTCTGTTGGAAGAAGGGTTTTTCCCTTCCTTTTGGGGTTTTTGTTGCCTTTTTTTTTTCTTTTTTCTTTGTAAAATTTTGGAGAAGGGAAGTCGGAACACAAGGAAGGACCGCTCACCCGCGGACTCAGGGCTGGCGGCGGGACTCCAGGACCCTGGGTCCAGCATGGAGGTGGTGGACCCGCAGCAGCTGGGCATGTTCACGGAGGGCGAGCTGATGTCGGTGGGTATGGACACGTTCATCCACCGCATCGACTCCACCGAGGTCATCTACCAGCCGCGCCGCAAGCGGGCCAAGCTCATCGGCAAGTACCTGATGGGGGACCTGCTGGGGGAAGGCTCTTACGGCAAGGTGAAGGAGGTGCTGGACTCGGAGACGCTGTGCAGGAGGGCCGTCAAGATCCTCAAGAAGAAGAAGTTGCGAAGGATCCCCAACGGGGAGGCCAACGTGAAGAA-G Peutz-Jeghers syndrome Pathogenic (Mar 21, 2018)576830
19-1205816-G-A Peutz-Jeghers syndrome Uncertain significance (Jan 12, 2018)328202
19-1205817-G-T Peutz-Jeghers syndrome Uncertain significance (Jan 12, 2018)892102
19-1205822-G-GGCGGCCCGGGGCGCCCGCGAGTGAGGCGCGGGGCGGCGAAGGGAGCGCGGGTGGCGGCACTTGCTGCCGCGGCCTTGGATGGGCTGGGCCCCCCTCGCCGCTCCGCCTCCTCCACACGCGCGGCGGCCGCGGCGAGGGGGACGCGCCGCCCGGGGCCCGGCACCTTCGGGAACCCCCCGGCCCGGAGCCTGCGGCCTGCGCCGCCTCGGCCGCCGGGAGCCCCGTGGAGCCCCCGCCGCCGCGCCGCCCCGCGGACCGGACGCTGAGGGCACTCGGGGCGGGGCGCGCGCTCGGGCAGACGTTTGCGGGGAGGGGGGCGCCTGCCGGGCCCCGGCGACCACCTTGGGGGTCGCGGGCCGGCTCGGGGGGCGCCCAGTGCGGGCCCTCGCGGGCGCCGGGCAGCGACCAGCCCTGAGCGGAGCTGTTGGCCGCGGCGGGAGGCCTCCCGGACGCCCCCAGCCCCCCGAACGCTCGCCCGGGCCGGCGGGAGTCGGCGCCCCCCGGGAGGTCCGCTCGGTCGTCCGCGGCGGAGCGTTTGCTCCTGGGACAGGCGGTGGGACCGGGGCGTCGCCGGAGACGCCCCCAGCGAAGTTGGGCTCTCCAGGTGTGGGGGTCCCGGGGGGTAGCGACGTCGCGGACCCGGCCTGTGGGATGGGCGGCCCGGAGAAGACTGCGCTCGGCCGTGTTCATACTTGTCCGTGGGCCTGAGGTCCCCGGAGGATGACCTAGCACTGAAAAGCCCCGGCCGGCCTCCCCAGGGTCCCCGAGGACGAAGTTGACCCTGACCGGGCCGTCTCCCAGTTCTGAGGCCCGGGTCCCACTGGAACTCGCGTCTGAGCCGCCGTCCCGGACCCCCGGTGCCCGCCGGTCCGCAGACCCTGCACCGGGCTTGGACTCGCAGCCGGGACTGACGTGTAGAACAATCGTTTCTGTTGGAAGAAGGGTTTTTCCCTTCCTTTTGGGGTTTTTGTTGCCTTTTTTTTTTCTTTTTTCTTTGTAAAATTTTGGAGAAGGGAAGTCGGAACACAAGGAAGGACCGCTCACCCGCGGACTCAGGGCTGGCGGCGGGACTCCAGGACCCTGGGTCCAGCATGGAGGTGGTGGACCCGCAGCAGCTGGGCATGTTCACGGAGGGCGAGCTGATGTCGGTGGGTATGGACACGTTCATCCACCGCATCGACTCCACCGAGGTCATCTACCAGCCGCGCCGCAAGCGGGCCAAGCTCATCGGCAAGTACCTGATGGGGGACCTGCTGGGGGAAGGCTCTTACGGCAAGGTGAAGGAGGTGCTGGACTCGGAGACGCTGTGCAGGAGGGCCGTCAAGATCCTCAAGAAGAAGAAGTTGCGAAGGATCCCCAACGGGGAGGCCAACGTGAAGAAGTAAGTATGGCTTGCTGGGGTCGGGGCCGGGCCGGGCCAGTCACGGTGCTGATGGTTCTGTCTTCCTTCCTTCTCTCCTCCCTCCCTCCCTTACTTCCTCTTAACACCCTGAGCTGGACCCGTCTGGCGCCTGTGTCCTCCGTGCCAGGGAGAGCGTGGTTGGGGGCCTGCGTTACGGACTTTCACTCAGGCAAGGCCAGTTGTCGCAGCGGGGCGTGCGTTTGCATGGGCTCTTGGACTCCAGTTAAAATGCCCTGGTAGCGAAACCCTCCTGAGAAGGGAGCGGCCCCCAATCCCCTAAGACTAGCCCCTTGGCTCCCCCAGCTGTCCAAGGAGCAGAGGCGCCCAGTGGAATCAGCCTGTGTTTGTTTGGGCCCCGAGAGTTTGTGTGCGGCCGCCAACACGTTTTCTGCGCAGTGTGTGGCCGTTACCGGGGCCAGGCGAAATGTGATTTGTTTATCCTGTCAGAGGGGAACCCTGGGCTGCCAAAAATAACTGTTTGCACCGGCTTATCAGTCAGCAGGAGGGAAACGTAGCCTTTCCTCATTTGCCAGGGATGTGACGCTGGAAGCATCCCTGGCCCCCGGGGCTGGAAGCCCTGCCCGAGGGGGACTGTGCCTCCCTCCCGAATTGCATCCGGAAGACCTTACTTTTCCAACTGACTTCTTCAGGCACGGGGCTGCCGCTGGGCATCCCGGACGCCTCTGCATCTGTGCGCGGAGAAGCTCCTACCTAGGGCAGCACTGGCCGGCCTGAGCCTCTCCCAGCTGGTGGGGGTGGCCGGGGGTGTCCCTGCCTTATCGCAGCCAGACAC Hereditary cancer-predisposing syndrome Likely benign (Dec 01, 2023)3231731
19-1205859-C-T Peutz-Jeghers syndrome Uncertain significance (Jun 14, 2016)328203
19-1205890-C-T Peutz-Jeghers syndrome Benign (Jul 26, 2019)328204
19-1205989-C-T Peutz-Jeghers syndrome Uncertain significance (Jan 13, 2018)328205
19-1206021-C-T Peutz-Jeghers syndrome Uncertain significance (Jan 13, 2018)892103
19-1206079-C-T Peutz-Jeghers syndrome Uncertain significance (Jan 13, 2018)892104
19-1206108-C-T Peutz-Jeghers syndrome Uncertain significance (Jan 12, 2018)892105
19-1206131-G-A Peutz-Jeghers syndrome Uncertain significance (Jan 13, 2018)892106
19-1206139-G-A Peutz-Jeghers syndrome Uncertain significance (Jan 12, 2018)892107
19-1206140-C-T Peutz-Jeghers syndrome Uncertain significance (Jan 12, 2018)888657
19-1206191-G-T Peutz-Jeghers syndrome Uncertain significance (Jan 12, 2018)328206
19-1206274-GC-G Peutz-Jeghers syndrome Uncertain significance (Jun 14, 2016)328207
19-1206324-C-T Peutz-Jeghers syndrome Uncertain significance (Apr 27, 2017)888658
19-1206327-G-C Peutz-Jeghers syndrome Uncertain significance (Jun 14, 2016)328208
19-1206334-G-A Peutz-Jeghers syndrome Benign (Apr 16, 2018)888659
19-1206337-C-T Peutz-Jeghers syndrome Benign (Jan 13, 2018)328209
19-1206352-G-C Peutz-Jeghers syndrome Benign (Jan 12, 2018)328210

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
STK11protein_codingprotein_codingENST00000326873 939023
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.9930.00660120835011208360.00000414
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.602032780.7300.00001762817
Missense in Polyphen36109.450.328921226
Synonymous-2.901671261.330.00000921822
Loss of Function3.87119.40.05168.21e-7231

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000009180.00000918
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non- AMPK family proteins such as STRADA, PTEN and possibly p53/TP53. Acts as a key upstream regulator of AMPK by mediating phosphorylation and activation of AMPK catalytic subunits PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition of signaling pathways that promote cell growth and proliferation when energy levels are low, glucose homeostasis in liver, activation of autophagy when cells undergo nutrient deprivation, and B-cell differentiation in the germinal center in response to DNA damage. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Required for cortical neuron polarization by mediating phosphorylation and activation of BRSK1 and BRSK2, leading to axon initiation and specification. Involved in DNA damage response: interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to participate in transcription activation. Able to phosphorylate p53/TP53; the relevance of such result in vivo is however unclear and phosphorylation may be indirect and mediated by downstream STK11/LKB1 kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis via interaction with p53/TP53: translocates to the mitochondrion during apoptosis and regulates p53/TP53-dependent apoptosis pathways. In vein endothelial cells, inhibits PI3K/Akt signaling activity and thus induces apoptosis in response to the oxidant peroxynitrite (in vitro). Regulates UV radiation-induced DNA damage response mediated by CDKN1A. In association with NUAK1, phosphorylates CDKN1A in response to UV radiation and contributes to its degradation which is necessary for optimal DNA repair (PubMed:25329316). {ECO:0000269|PubMed:11430832, ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:14517248, ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15016379, ECO:0000269|PubMed:15733851, ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:25329316}.;
Disease
DISEASE: Peutz-Jeghers syndrome (PJS) [MIM:175200]: An autosomal dominant disorder characterized by melanocytic macules of the lips, multiple gastrointestinal hamartomatous polyps and an increased risk for various neoplasms, including gastrointestinal cancer. {ECO:0000269|PubMed:10408777, ECO:0000269|PubMed:12372054, ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:21411391, ECO:0000269|PubMed:9425897, ECO:0000269|PubMed:9428765, ECO:0000269|PubMed:9760200, ECO:0000269|PubMed:9837816}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. {ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Note=Defects in STK11 are associated with some sporadic cancers, especially lung cancers. Frequently mutated and inactivated in non-small cell lung cancer (NSCLC). Defects promote lung cancerigenesis process, especially lung cancer progression and metastasis. Confers lung adenocarcinoma the ability to trans- differentiate into squamous cell carcinoma. Also able to promotes lung cancer metastasis, via both cancer-cell autonomous and non- cancer-cell autonomous mechanisms.;
Pathway
PI3K-Akt signaling pathway - Homo sapiens (human);mTOR signaling pathway - Homo sapiens (human);Adipocytokine signaling pathway - Homo sapiens (human);Tight junction - Homo sapiens (human);Autophagy - animal - Homo sapiens (human);FoxO signaling pathway - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Longevity regulating pathway - Homo sapiens (human);Metformin Pathway, Pharmacodynamic;WNT-Ncore;EGF-Ncore;AMP-activated Protein Kinase (AMPK) Signaling;Integrated Breast Cancer Pathway;Polycystic Kidney Disease Pathway;mir-124 predicted interactions with cell cycle and differentiation;ATM Signaling Network in Development and Disease;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Signal Transduction;Gene expression (Transcription);Generic Transcription Pathway;AMPK inhibits chREBP transcriptional activation activity;RNA Polymerase II Transcription;Energy dependent regulation of mTOR by LKB1-AMPK;mTOR signalling;Metabolism;TGF_beta_Receptor;EGFR1;Regulation of TP53 Activity through Phosphorylation;Regulation of TP53 Activity;Transcriptional Regulation by TP53;Integration of energy metabolism;LKB1 signaling events (Consensus)

Recessive Scores

pRec
0.307

Intolerance Scores

loftool
0.112
rvis_EVS
-0.54
rvis_percentile_EVS
20.54

Haploinsufficiency Scores

pHI
0.531
hipred
Y
hipred_score
0.783
ghis
0.629

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
S
essential_gene_gene_trap
K
gene_indispensability_pred
E
gene_indispensability_score
0.998

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Stk11
Phenotype
endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); muscle phenotype; digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; reproductive system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype;

Zebrafish Information Network

Gene name
stk11
Affected structure
intestinal epithelium
Phenotype tag
abnormal
Phenotype quality
flattened

Gene ontology

Biological process
regulation of cell growth;tissue homeostasis;vasculature development;protein phosphorylation;protein dephosphorylation;autophagy;cellular response to DNA damage stimulus;cell cycle arrest;spermatogenesis;axonogenesis;negative regulation of cell population proliferation;response to ionizing radiation;positive regulation of autophagy;establishment of cell polarity;negative regulation of cell growth;positive regulation of transforming growth factor beta receptor signaling pathway;activation of protein kinase activity;glucose homeostasis;anoikis;positive thymic T cell selection;protein autophosphorylation;regulation of dendrite morphogenesis;positive regulation of axonogenesis;T cell receptor signaling pathway;Golgi localization;regulation of protein kinase B signaling;canonical Wnt signaling pathway;negative regulation of epithelial cell proliferation involved in prostate gland development;cellular response to UV-B;intrinsic apoptotic signaling pathway by p53 class mediator;negative regulation of canonical Wnt signaling pathway;dendrite extension;negative regulation of cold-induced thermogenesis;positive regulation of protein localization to nucleus;regulation of signal transduction by p53 class mediator;negative regulation of TORC1 signaling
Cellular component
nucleus;nucleoplasm;cytoplasm;mitochondrion;cytosol;membrane;extracellular exosome
Molecular function
magnesium ion binding;p53 binding;protein serine/threonine kinase activity;protein binding;ATP binding;LRR domain binding;protein kinase activator activity